Global Cannabis Applications Corp (GCAC) (CSE:APP, FRA:2FA, OTCQB:FUAPF), a leading developer of innovative data technologies for the cannabis industry, is pleased to announce that it has signed a Collaboration Agreement (the “Agreement”) with the Foundation of Cannabis Unified Standards (“FOCUS”) to establish legal cannabis programs in emerging markets and increase patient efficacy data supply, with the ultimate goal of improving health and safety.

Foundation of Cannabis Unified Standards (FOCUS) was established in 2014 as the Cannabis Health and Safety Organization in an effort to protect public health, consumer safety, and safeguard the environment. FOCUS is a global non-profit, with international operations in the U.S., Mexico, Canada, Australia, Columbia and New Zealand.


FOCUS Standards provide current good manufacturing practice (GMP) guidelines for all key areas of the cannabis industry including Cultivation, Retail, Extraction, Infused Products, Laboratory, Security, Sustainability, and Packaging & Labeling. The internationally accepted cannabis standards developed by FOCUS, align with Good Manufacturing Practices (GMP) guidelines established by the World Health Organization, as well as US Code of Federal Regulations. FOCUS provides application services, gap assessments, consulting, training, risk management and certification, as well as an array of services for government agencies.

GCAC is developing the Citizen Green Community, a trusted source for medical cannabis knowledge, for patients, regulators and cannabis companies. The Citizen Green token economy will enable GCAC to reward users and organizations for sharing their medical data, experience and procedures. The Citizen Green platform is based on technologies such as blockchain and artificial intelligence, to give users ownership over their data in a secure environment that ensures the integrity of the information.

“This agreement will enable FOCUS and GCAC to leverage each others’ relationships and expertise to serve global cannabis markets,” said Lezli Engelking, Founder and Executive Chair of FOCUS. “We look forward to helping GCAC collect patient efficacy data, to further our mission of protecting public health and consumer safety in the cannabis industry.”

“We are keen to work with FOCUS and learn from their experience in emerging cannabis markets, where FOCUS is the expert at developing regulations for the global cannabis industry,” said Brad Moore, CEO of GCAC. “GCAC and FOCUS are aligned in improving health, safety and patient outcomes in the cannabis industry.”

About Foundation of Cannabis Unified Standards

Established in 2014 as The Cannabis Health and Safety Organization, FOCUS is a 501c3 non-profit that addresses the many shortcomings in quality, safety, and consistency that have become evident with the explosive growth of the global cannabis industry. FOCUS is not a cannabis company, an industry trade association, nor an advocacy organization. FOCUS is an unbiased, third-party with no financial stake in – or funding from – the cannabis industry. FOCUS does not advocate on behalf of or push cannabis policy. FOCUS exists to help assure the rapidly growing global cannabis industry has the necessary protections in place for the health, safety, success, and welfare of everyone. This autonomy fosters a principled, objective organization that protects end users, and acts as the much-needed neutral, nonpartisan bridge between industry and regulatory.

About Global Cannabis Applications Corp.

Global Cannabis Applications Corp. is a global leader in designing, developing, marketing and acquiring innovative data technologies for the cannabis industry. The Citizen Green platform is the world’s first end-to-end – from patient to regulator – medical cannabis data solution. It uses six core technologies: mobile applications, artificial intelligence, regtech, smart databases, blockchain and digital reward tokens, to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in the medical cannabis community. Managed by digital and cannabis industry experts, GCAC is focused on viral global expansion by providing the best digital experience in the cannabis market.

For more information about the Company, please visit online at www.cannappscorp.com, or review its profiles www.sedar.com and on the Canadian Securities Exchange’s website (www.thecse.com).

To schedule an interview, please contact:

Bradley Moore

Chief Executive Officer

Telephone: 514.561.9091

Email: bmoore@cannappscorp.com

For more information, please contact:

Corporate Communications

Telephone: 1.855.269.9554

Email: info@cannappscorp.com

www.cannappscorp.com

Forward-Looking Information

This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of GCAC. Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC. Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct. Forward-looking statements contained in this news release are made as of the date of this news release. GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information.

Click here to connect with Global Cannabis Applications Corp (GCAC) (CSE:APP, FRA:2FA, OTCQB:FUAPF) and receive an Investors Presentation.

Source: www.thenewswire.com

Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

Keep reading... Show less

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less